PRTA Dec 2024 30.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:59AM EDT. Market open.
| Previous close | 2.1100 |
| Open | 2.1100 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 30.00 |
| Expiry date | 2024-12-20 |
| Day's range | 2.1100 - 2.1100 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
ZacksProthena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Business WireProthena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
DUBLIN, May 28, 2024--Prothena today announced that Bristol Myers Squibb obtained the exclusive global license for PRX019 and will pay Prothena $80 million.
Simply Wall St.News Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) Forecasts
Celebrations may be in order for Prothena Corporation plc ( NASDAQ:PRTA ) shareholders, with the analysts delivering a...
© 2024 Yahoo. All rights reserved.